Ratliff John D 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 14, 2018
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Award
Non-qualified Stock Options
2018-02-12+17,100→ 17,100 totalExercise: $168.49From: 2019-02-12Exp: 2028-02-11→ Common Stock (17,100 underlying) - Award
Restricted Stock Unit
2018-02-12+4,390→ 14,217 total→ Common Stock (4,390 underlying)
Footnotes (5)
- [F1]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F2]The option vests in three equal installments beginning on the date reflected in this column.
- [F3]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F4]The Restricted Stock Units vest in three equal annual installments beginning on 2/12/19.
- [F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.